HOWL|EPS -$0.20|Rev $0|Net Loss $8.4MWerewolf Therapeutics, Inc. reported a diluted loss of -$0.20 per share for the fourth quarter of 2025, representing a 56.5% improvement from the -$0.46 per share loss recorded in the same period last year. The biopharmaceutical company, which focuses on developing therapeutics engineered to stimulate the body’s immune system for cancer treatment, posted a net loss of $8.4M for the quarter.
The Cambridge-based biotech generated $0 in revenue for the quarter, consistent with its development-stage status as it advances its pipeline of immune-stimulating therapeutics. The company specializes in creating treatments designed to harness the body’s natural defenses against cancer and other immune-mediated conditions.
Despite operating in the cash-intensive phase of drug development, Werewolf Therapeutics has maintained support from the analyst community. Wall Street consensus currently stands at 9 buy ratings, 3 hold ratings, and 0 sell recommendations for the NASDAQ-traded stock. The narrowing of losses year-over-year reflects the company’s efforts to manage its burn rate while progressing its clinical programs.
A detailed analysis of Werewolf Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings first appeared on Alphastreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
